Fierce Biotech Layoff Tracker 2024: Affimed dissolves research and preclinical teams; 175 Exelixis employees to exit

08 Jan 2024
www.fiercebiotech.com
Phase 3Phase 2ImmunotherapyGene Therapy
Fierce Biotech Layoff Tracker 2024: Affimed dissolves research and preclinical teams; 175 Exelixis employees to exit
Preview
Source: FierceBiotech
If you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking industry layoffs.
Last year, we tallied 187 total layoffs among biotech companies, a 57% jump compared to 119 in 2022. We hope that trend reverses itself in 2024.
As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team and let us know.
January—8 companies
January 8 - Affimed: Affimed is dissolving its research and preclinical development teams, cutting 50% of its staff as a result. The company says all funds will go toward its clinical-stage programs, which include a package of innate cell engages. Release
January 8 - Exelixis: Around 175 Exelixis employees are heading for the exits in the coming months, a workforce reduction that represents 13% of the company's total workforce. Story
January 5 - NanoString Technologies: To cut costs, the company is laying off about 50 employees, representing 9% of its global workforce. The workforce reduction is expected to be complete by March 31. Release
January 5 - Senti Bio: The cell and gene therapy biotech is cutting its workforce down by 37% and prioritizing resources on SENTI-202, an off-the-shelf CAR-NK candidate being tested for the treatment of acute myeloid leukemia and other hematologic malignancies in a phase 1 clinical trial, with the first patient expected to be dosed in the second quarter of this year. Release
January 5 - AlloVir: Less than a month after suffering a triple phase 3 failure, the allogeneic T cell immunotherapy biotech is cutting 95% of its workforce. The cuts are expected to take place mostly in the first quarter of this year and finish up by Apr. 15. Story
January 4 - Aera Therapeutics: The genetic medicine company has laid off a quarter of its staff. The biotech only just emerged from stealth a year ago in February 2023 with $193 million. Story
January 4 - Intellia Therapeutics: The CRISPR company is laying off 15% of its team after pausing exploratory research work. Story
January 4 - Pfizer: The Big Pharma's vaccine R&D site in Pearl River, NY is expecting to lay off 285 employees starting in February, according to a New York WARN notice. The spot is one of Pfizer’s nine major R&D sites and currently employs 1,012 workers. The layoff wave is set to conclude by March 25. Release
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.